Sallyport Commercial Finance (Sallyport) has announced a groundbreaking US$10m in accounts receivable finance for a prominent pharmaceutical company – Shield Therapeutics Inc. This financing marks a pivotal moment for the organisation, which is fervently navigating its commercialisation journey in North America amidst soaring sales figures.
The infusion of US$10m in accounts receivable financing will provide the pharmaceutical company with the necessary impetus to further bolster its operations across North America. Despite the intricacies involved in orchestrating this financial arrangement, with the pharmaceutical firm operating under a UK parent company, Sallyport’s global footprint, including key offices in both the UK and the US, facilitated the seamless execution of this complex deal, ensuring swift and effective funding for the client.
